TOFAcitinib in SARS-CoV2 Pneumonia
NCT04332042
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
50
Enrollment
OTHER
Sponsor class
Conditions
SARS-COv2 Related Interstitial Pneumonia
Interventions
DRUG:
Tofacitinib
Sponsor
Università Politecnica delle Marche